(Q46530085)

English

Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial

scientific article published in May 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

metabolic syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

Giuseppe Derosa

1

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

author name string

A V Gaddi

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

L Ciccarelli

3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

E Fogari

4

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

M Ghelfi

5

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

I Ferrari

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

A F G Cicero

7

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

publication date

1 May 2005

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

Journal of International Medical Research

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

33

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

284-294

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

Rationale and options for combination therapy in the treatment of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Combining sulfonylureas and other oral agents

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Clinical review of glimepiride

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Thiazolidinediones -- some recent developments

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Determination of total serum insulin (IRI) in insulin-treated diabetic patients.

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Elevated serum lipoprotein(a) level is an independent marker of severity of thoracic aortic atherosclerosis

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Relation of lipid and lipoprotein(a) to ischaemic stroke

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Type of diabetes and waist-hip ratio are important determinants of serum lipoprotein (a) levels in diabetic patients.

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in Type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Folate and homocysteine metabolism: therapeutic targets in cardiovascular and neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Effect of Homocysteine-Lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside

1 reference

https://api.crossref.org/works/10.1177%2F147323000503300303

21 January 2018

Identifiers

10.1177/147323000503300303

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15938589

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46530085&oldid=2116279602"